Translational Development Acquisition (TDAC) Non Operating Income (2024 - 2026)

Translational Development Acquisition's Non Operating Income history runs 3 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• Quarterly Non Operating Income fell 11.83% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (changed N/A YoY) and the FY2025 annual result came in at $7.3 million, up 5729.44% from the prior year.
• Non Operating Income was $1.6 million for Q1 2026 at Translational Development Acquisition, down from $1.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $1.9 million in Q3 2025 and bottomed at $125346.0 in Q4 2024.
• A 3-year average of $1.5 million and a median of $1.8 million in 2025 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2025 — Non Operating Income soared 1302.7% — and 2026, when it slipped 11.83%.
• Translational Development Acquisition's Non Operating Income stood at $125346.0 in 2024, then surged by 1302.7% to $1.8 million in 2025, then retreated by 8.21% to $1.6 million in 2026.
• Business Quant data shows TDAC's Non Operating Income at $1.6 million in Q1 2026, $1.8 million in Q4 2025, and $1.9 million in Q3 2025.